U.S. markets close in 55 minutes
  • S&P 500

    4,070.88
    -5.69 (-0.14%)
     
  • Dow 30

    34,419.29
    +24.28 (+0.07%)
     
  • Nasdaq

    11,444.53
    -37.92 (-0.33%)
     
  • Russell 2000

    1,888.04
    +6.36 (+0.34%)
     
  • Crude Oil

    80.18
    -1.04 (-1.28%)
     
  • Gold

    1,811.30
    -3.90 (-0.21%)
     
  • Silver

    23.42
    +0.57 (+2.51%)
     
  • EUR/USD

    1.0539
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    3.5150
    -0.0140 (-0.40%)
     
  • GBP/USD

    1.2295
    +0.0039 (+0.31%)
     
  • USD/JPY

    134.4320
    -0.8740 (-0.65%)
     
  • BTC-USD

    16,988.37
    +37.72 (+0.22%)
     
  • CMC Crypto 200

    403.61
    +2.18 (+0.54%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

JERUSALEM, Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer, BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida. RAFT provides a forum for academic and industrial scientists to discuss the latest developments in fermentation technology.

 

BiondVax Pharmaceuticals Logo
BiondVax Pharmaceuticals Logo

 

Presentation Details:
Topic: Nano-sized solution for a massive challenge: NanoAbs as a platform for COVID-19, asthma, and psoriasis therapies
When: Tuesday, November 8 at 3:35pm (ET)
Where: Caribe Royale Orlando - Grand Sierra E

The presentation will focus on BiondVax's yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs). NanoAbs are monoclonal antibody (mAbs) 'bio-betters' in terms of cost, heat and shear force stability, high target affinity, and potential convenience to patients. BiondVax's lead NanoAb candidate, for treatment of COVID-19, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies. Development is also underway for additional NanoAbs addressing diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis and asthma.

Further information regarding the RAFT conference is available via the conference website at https://www.simbhq.org/raft/.

About BiondVax

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. www.biondvax.com.

Contact Details

Joshua Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financings, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, the therapeutic and commercial potential of nanosized antibodies (NanoAbs); and the timing of NanoAb proof-of-concept studies and clinical trials. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that the company may not raise capital on acceptable terms or at all, the risk that the company will not submit a compliance plan acceptable to Nasdaq, the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that clinical trials relating to NanoAbs will fail in whole or in part; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire rights to additional product opportunities; BiondVax's ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo - https://mma.prnewswire.com/media/615570/BiondVax_Pharmaceuticals_Logo.jpg

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/biondvax-to-present-at-recent-advances-in-fermentation-technology-raft-14-conference-301667888.html

SOURCE BiondVax Pharmaceuticals Ltd.